MoonLake Immunotherapeutics (MLTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $12.30 (-0.40%), Market cap $1.22B, 52-week low–high $6.25 ~ $61.99.
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Financial statements, price targets, institutional (13F) holdings and related news for MoonLake Immunotherapeutics are updated in real time on BlackAll Trade.
MoonLake Immunotherapeutics trades at $12.30 (-0.40%). Real-time quotes and charts are available on BlackAll Trade.
MoonLake Immunotherapeutics has a market cap of about $1.22B.
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and